EP3880246A4 - Procédé d'amélioration de la prédiction de la réponse pour des patients cancéreux traités par immunothérapie - Google Patents

Procédé d'amélioration de la prédiction de la réponse pour des patients cancéreux traités par immunothérapie Download PDF

Info

Publication number
EP3880246A4
EP3880246A4 EP19885138.8A EP19885138A EP3880246A4 EP 3880246 A4 EP3880246 A4 EP 3880246A4 EP 19885138 A EP19885138 A EP 19885138A EP 3880246 A4 EP3880246 A4 EP 3880246A4
Authority
EP
European Patent Office
Prior art keywords
immunotherapy
response
cancer patients
patients treated
improving prediction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19885138.8A
Other languages
German (de)
English (en)
Other versions
EP3880246A1 (fr
Inventor
Nicholas C. DRACOPOLI
Gustavo CERQUEIRA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Personal Genome Diagnostics Inc
Original Assignee
Personal Genome Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Personal Genome Diagnostics Inc filed Critical Personal Genome Diagnostics Inc
Publication of EP3880246A1 publication Critical patent/EP3880246A1/fr
Publication of EP3880246A4 publication Critical patent/EP3880246A4/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP19885138.8A 2018-11-15 2019-11-15 Procédé d'amélioration de la prédiction de la réponse pour des patients cancéreux traités par immunothérapie Pending EP3880246A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862767979P 2018-11-15 2018-11-15
PCT/US2019/061710 WO2020102674A1 (fr) 2018-11-15 2019-11-15 Procédé d'amélioration de la prédiction de la réponse pour des patients cancéreux traités par immunothérapie

Publications (2)

Publication Number Publication Date
EP3880246A1 EP3880246A1 (fr) 2021-09-22
EP3880246A4 true EP3880246A4 (fr) 2022-08-10

Family

ID=70727341

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19885138.8A Pending EP3880246A4 (fr) 2018-11-15 2019-11-15 Procédé d'amélioration de la prédiction de la réponse pour des patients cancéreux traités par immunothérapie

Country Status (6)

Country Link
US (1) US20200157642A1 (fr)
EP (1) EP3880246A4 (fr)
JP (1) JP2022513068A (fr)
AU (1) AU2019379167A1 (fr)
CA (1) CA3120200A1 (fr)
WO (1) WO2020102674A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116134155A (zh) * 2020-08-26 2023-05-16 瑞泽恩制药公司 通过施用pd-1抑制剂治疗癌症的方法
CN111979323A (zh) * 2020-08-28 2020-11-24 深圳裕策生物科技有限公司 用于预测肿瘤免疫治疗效果的生物标志物检测方法及系统
CN112029861B (zh) * 2020-09-07 2021-09-21 臻悦生物科技江苏有限公司 基于捕获测序技术的肿瘤突变负荷检测装置及方法
EP4330436A1 (fr) * 2021-04-30 2024-03-06 Genentech, Inc. Méthodes thérapeutiques et diagnostiques et compositions contre le cancer
WO2023196390A1 (fr) * 2022-04-06 2023-10-12 Foundation Medicine, Inc. Biomarqueurs d'aneuploïdie associés à une réponse à des thérapies anticancéreuses

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017151517A1 (fr) * 2016-02-29 2017-09-08 Foundation Medicine, Inc. Méthodes de traitement du cancer
WO2017151502A1 (fr) * 2016-02-29 2017-09-08 Genentech, Inc. Méthodes thérapeutiques et de diagnostic du cancer
WO2018005276A1 (fr) * 2016-06-29 2018-01-04 The Johns Hopkins University Néoantigènes utilisés comme cibles pour l'immunothérapie
WO2018132749A1 (fr) * 2017-01-13 2018-07-19 The General Hospital Corporation Résistance à la thérapie de blocage des point de contrôle
WO2018183928A1 (fr) * 2017-03-31 2018-10-04 Bristol-Myers Squibb Company Procédés de traitement de tumeur

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201703541PA (en) * 2014-11-13 2017-05-30 Univ Johns Hopkins Checkpoint blockade and microsatellite instability
MA40737A (fr) * 2014-11-21 2017-07-04 Memorial Sloan Kettering Cancer Center Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017151517A1 (fr) * 2016-02-29 2017-09-08 Foundation Medicine, Inc. Méthodes de traitement du cancer
WO2017151502A1 (fr) * 2016-02-29 2017-09-08 Genentech, Inc. Méthodes thérapeutiques et de diagnostic du cancer
WO2018005276A1 (fr) * 2016-06-29 2018-01-04 The Johns Hopkins University Néoantigènes utilisés comme cibles pour l'immunothérapie
WO2018132749A1 (fr) * 2017-01-13 2018-07-19 The General Hospital Corporation Résistance à la thérapie de blocage des point de contrôle
WO2018183928A1 (fr) * 2017-03-31 2018-10-04 Bristol-Myers Squibb Company Procédés de traitement de tumeur

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ALEXANDRA SNYDER ET AL: "Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 371, no. 23, 4 December 2014 (2014-12-04), US, pages 2189 - 2199, XP055262135, ISSN: 0028-4793, DOI: 10.1056/NEJMoa1406498 *
ANONYMOUS: "Caris Molecular Intelligence: Total Mutational Load - Immune Checkpoint Inhibitors Response", CARIS LIFE SCIENCES, 10 August 2016 (2016-08-10), pages 1 - 2, XP055889553 *
CERQUEIRA GUSTAVO C. ET AL: "Abstract 3515: Functional antigen presentation is required to interpret the tumor mutation burden (TMB) test | Cancer Research | American Association for Cancer Research", 1 July 2019 (2019-07-01), XP055936401, Retrieved from the Internet <URL:https://aacrjournals.org/cancerres/article/79/13_Supplement/3515/635472/Abstract-3515-Functional-antigen-presentation-is> [retrieved on 20220628] *
RIZVI HIRA ET AL: "Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing", 1 March 2018 (2018-03-01), XP055867012, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6075848/pdf/JCO.2017.75.3384.pdf> [retrieved on 20211129] *
See also references of WO2020102674A1 *
STEUER CONOR E ET AL: "JOURNAL OF CLINICAL ONCOLOGY Tumor Mutation Burden: Leading Immunotherapy to the Era of Precision Medicine?", 1 March 2018 (2018-03-01), XP055936646, Retrieved from the Internet <URL:https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2017.76.8770> [retrieved on 20220629] *

Also Published As

Publication number Publication date
JP2022513068A (ja) 2022-02-07
US20200157642A1 (en) 2020-05-21
CA3120200A1 (fr) 2020-05-22
EP3880246A1 (fr) 2021-09-22
AU2019379167A1 (en) 2021-06-03
WO2020102674A1 (fr) 2020-05-22

Similar Documents

Publication Publication Date Title
EP3565844B8 (fr) Procédés de traitement du cancer à l&#39;aide d&#39;anticorps anti-pd-1
EP3880246A4 (fr) Procédé d&#39;amélioration de la prédiction de la réponse pour des patients cancéreux traités par immunothérapie
EP3524689A4 (fr) Méthode de prédiction du pronostic chez une patiente atteinte du cancer du sein
EP3883580A4 (fr) Méthodes de traitement de cancers
EP3775171A4 (fr) Procédés de traitement d&#39;un cancer résiduel minimal
IL285807A (en) Immunotherapy for cancer treatment
EP3787625A4 (fr) Méthodes de traitement du cancer
EP4017489A4 (fr) Méthode de traitement de cancers associés à kras
EP3628010A4 (fr) Méthode de traitement de tumeur immunothérapeutique
EP3820461A4 (fr) Méthode de traitement du cancer
EP3908650A4 (fr) Méthodes de traitement du cancer
EP3891184A4 (fr) Méthode de traitement d&#39;affections neutrophiles
IL289811A (en) A method for treating cancer
EP3952858A4 (fr) Procédé de traitement de tumeurs
EP3852816A4 (fr) Méthodes de traitement de cancer
EP3781215A4 (fr) Méthodes de traitement du cancer
EP3894561A4 (fr) Procédés de traitement du cancer
EP3893869A4 (fr) Nouvelle approche pour le traitement du cancer utilisant l&#39;immunomodulation
EP3768316A4 (fr) Procédé de traitement par médicament d&#39;immunothérapie
EP4072561A4 (fr) Méthodes de traitement du cancer
EP3801547A4 (fr) Procédés de traitement du cancer
EP3890780A4 (fr) Procédé de traitement
EP4058140A4 (fr) Méthodes de traitement d&#39;ascites
EP3934649A4 (fr) Procédés de traitement d&#39;une maladie avec du lévokétoconazole
AU2019904027A0 (en) Method of treating cancer

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210511

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40056430

Country of ref document: HK

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

A4 Supplementary search report drawn up and despatched

Effective date: 20220707

RIC1 Information provided on ipc code assigned before grant

Ipc: C12Q 1/6886 20180101ALI20220701BHEP

Ipc: C12Q 1/6827 20180101ALI20220701BHEP

Ipc: C12Q 1/68 20180101ALI20220701BHEP

Ipc: A61P 35/00 20060101ALI20220701BHEP

Ipc: A61K 39/395 20060101AFI20220701BHEP